Relating to requiring certain health care entities to submit notice of material change transactions to the attorney general and the attorney general's authority to conduct certain related studies; imposing civil and administrative penalties.
HB 2747 creates a new Chapter 15A in the Business & Commerce Code to require advance notice to the attorney general of certain “material change transactions” involving health care entities. Covered transactions include mergers, acquisitions, joint ventures, control changes, certain real estate transactions, and the formation of organizations used to administer contracts with health carriers, third-party administrators, pharmacy benefit managers, or providers. The notice must be filed at least 90 days before the transaction takes effect, and the attorney general is authorized to adopt rules governing the form and method of notice.
The bill also authorizes the attorney general to conduct market studies on health care concentration, competition, pricing, quality, availability, and the effects of completed transactions. To support those studies, state licensing or oversight agencies may be asked to collect nonproprietary information from health care and related entities and forward it to the attorney general. The bill makes the submitted information confidential, limits disclosure, and allows the attorney general to share it only with consent or with contracted experts and consultants subject to confidentiality requirements.
HB 2747 would expand state oversight of health care consolidation and ownership changes by creating a pre-transaction notice regime for a broad range of health care entities, including providers, facilities, provider organizations, pharmacy benefit managers, and health carriers. It would also give the attorney general new authority to investigate market concentration and study the competitive effects of health care transactions, while imposing civil penalties of up to $10,000 per violation for failure to provide required notice and administrative penalties of up to $1,000 per day for failure to provide requested information. The bill would primarily affect health care businesses, investors, and affiliated organizations engaging in mergers, acquisitions, affiliations, or governance changes in Texas.
The bill’s stated purpose is strongly pro-competition, reflecting a policy view that consolidation in health care markets has reduced competition and increased prices. The available context shows no recorded votes or committee testimony, but the bill advanced out of the House Public Health Committee and was reported to Calendars, suggesting it received sufficient committee support to move forward. Overall, the measure appears to be framed as a consumer-protection and antitrust enforcement bill rather than a regulatory rollback.
The main likely point of contention is the breadth of the reporting requirement and the attorney general’s expanded role in reviewing health care transactions. Health care entities, provider groups, and private equity or other investors could view the notice requirement, confidentiality provisions, and potential penalties as burdensome or as a barrier to routine business combinations and affiliations. Supporters are likely to emphasize the need to monitor consolidation, while critics may argue that the bill could chill investment, delay transactions, or sweep in transactions that do not meaningfully harm competition. The bill’s exceptions for small entities, clinical trial affiliations, graduate medical education, and single-physician hiring suggest an attempt to narrow the scope, but the definition of covered transactions remains broad.